Toll-like receptors direct antimicrobial immune responses— and driving arthritis? Diego KyburzSteffen Gay Invited Commentary Pages: 407 - 408
Threats to validity of observational studies on disease-modifying antirheumatic drug therapies for rheumatoid arthritis: New aspects after the fall of the pyramid and the rise of new therapeutics Daniel AletahaJosef S. Smolen Invited Commentary Pages: 409 - 412
The role of jo-1 in the immunopathogenesis of polymyositis: Current hypotheses Dana P. Ascherman OriginalPaper Pages: 425 - 430
Idiopathic inflammatory myopathies: A treatment update Chester V. Oddis OriginalPaper Pages: 431 - 436
Foreign cells in polymyositis: Could stem cell transplantation and pregnancy-derived chimerism lead to the same disease? Anne M. Stevens OriginalPaper Pages: 437 - 444
The assessment and importance of disease activity versus disease damage in patients with inflammatory myopathy Shabina M. Sultan OriginalPaper Pages: 445 - 450
Epidemiology of the rheumatic diseases of childhood Prudence J. Manners OriginalPaper Pages: 453 - 457
Microchimerism in children with rheumatic disorders: What does it mean? Ann M. Reed OriginalPaper Pages: 458 - 462
Outcome measures and medical progress: Why outcome measures are needed in childhood arthritis Francesco Zulian OriginalPaper Pages: 463 - 470
Rheumatic disease in native american children: Opportunities and challenge James N. JarvisSophia Y. Cleland OriginalPaper Pages: 471 - 476
Clinical trials in pediatric uveitis Lucila M. A. AgleLiza B. Vazquez-CobianThomas J. A. Lehman OriginalPaper Pages: 477 - 481
